Decreased fracture rate by mandating bone-protecting agents in the EORTC 1333/PEACE III trial comparing enzalutamide and Ra223 versus enzalutamide alone: an interim safety analysis
Tombal, BF Loriot, Y Saad, F McDermott, RS Elliott, Tony Rodriguez-Vida, A Nole, F Fournier, B Collette, L Gillessen, Silke
Tombal, BF
Loriot, Y
Saad, F
McDermott, RS
Elliott, Tony
Rodriguez-Vida, A
Nole, F
Fournier, B
Collette, L
Gillessen, Silke
Citations
Altmetric:
Abstract
Description
Date
2019
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Tombal BF, Loriot Y, Saad F, McDermott RS, Elliott T, Rodriguez-Vida A, et al. Decreased fracture rate by mandating bone-protecting agents in the EORTC 1333/PEACE III trial comparing enzalutamide and Ra223 versus enzalutamide alone: an interim safety analysis. J Clin Oncol. 2019;37(15_suppl):5007-.